The legal dispute highlights the growing competition between Novo Nordisk and Eli Lilly in the rapidly expanding GLP-1 market, where both companies are competing to develop and market treatments for obesity and type 2 diabetes.
The following milestones mark important progress in the consolidated federal litigation: Increased evidentiary standards for gastroparesis claims: Courts require plaintiffs alleging gastroparesis to support claims with objective gastric-emptying tests rather than symptoms alone, raising the bar for admissible medical evidence Daubert hearings on expert testimony: May 2025 hearings will determine whether plaintiffs medical experts can testify about causation potentially decisive rulings that could strengthen or weaken thousands of claims Short-form complaint process adoption: MDL implemented streamlined filing procedures to manage the influx of new cases efficiently while maintaining procedural fairness Monthly status conferences throughout 2025: Regular court meetings ensure ongoing case management and coordination as parties work through challenging scientific and legal issues In September 2025, Judge Marston allowed most plaintiffs claims to proceed after denying defendants motions to dismiss, including accusations that drugmakers failed to warn about gastrointestinal issues and misrepresented safety
Additionally, IL-6 can be secreted by FLSs and B cells in the RA synovium and has been closely linked to the pathogenesis of the disease [236]
So getting three faces right was incredibly difficult. Eventually, he made one, and with Tschps experiments in mice, they showed in a 2014 paper that this triple agonist was even more powerful than dual agonists
Under his guidance, every medical IV treatment is customized to address an individual's unique health requirements
Weight gain and metabolic disease are largely driven by lifestyle - diet, physical activity, sleep and long-term habits
